Please try another search
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Andre Choulika | 58 | 1999 | Co-Founder, CEO & Director |
Jean-Pierre Garnier | 76 | 2020 | Independent Non-Executive Chairman |
Marcela V. Maus | 46 | 2017 | Member of Clinical Advisory Board |
Ghulam J. Mufti | - | - | Member of Clinical Advisory Board |
Dietger Niederwieser | - | 2017 | Member of Clinical Advisory Board |
Ola Landgren | - | 2017 | Member of Clinical Advisory Board |
Kanti Rai | - | 2017 | Member of Clinical Advisory Board |
Catherine Bollard | 54 | 2017 | Member of Clinical Advisory Board |
Stephan A. Grupp | - | 2018 | Member of Clinical Advisory Board |
David J. D. Sourdive | 56 | 2000 | Deputy CEO, Executive VP of CMC & Manufacturing and Director |
Laurent Arthaud | 60 | 2011 | Director |
Marc Dunoyer | 72 | 2023 | Director |
Tyrell Rivers | 51 | 2023 | Director |
Pierre Bastid | 70 | 2011 | Independent Director |
Donald A. Bergstrom | 52 | 2021 | Independent Director |
Rainer J. Boehm | 64 | 2017 | Independent Director |
Axel-Sven Malkomes | 57 | 2022 | Independent Director |
Cecile Chartier | 57 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review